Ayurvedic Formulations with Potential Anticancer Activity: A Comprehensive Review of Traditional Wisdom and Modern Scientific Validation

Payal Subhash Ghode[1], Reshma Dilip Pawar[2], Sunil Baban Rathod[3], Anjali Gahininath Kekan[4], Shilpa Balu Rohile[5]

Sahakar Maharshi Kisanrao Varal Patil College of Pharmacy Nighoj (414306)

Abstract—**Cancer remains one of the most significant global health challenges, driving the pursuit of effective and less toxic therapeutic options. Ayurveda, the ancient Indian system of medicine, offers a rich repository of plant-based formulations that have long been employed for various ailments, including tumors. This review aims to bridge traditional Ayurvedic knowledge with contemporary scientific evidence, highlighting formulations that exhibit promising anticancer activity. Key classical preparations such as Triphala, Ashwagandha (Withania somnifera), Guduchi (Tinospora cordifolia), and Curcuma longa have been documented for their antiproliferative, pro-apoptotic, anti-inflammatory, and immunomodulatory effects. Modern pharmacological investigations and preclinical studies provide growing support for these traditional claims, while ongoing clinical trials continue to clarify their therapeutic potential and safety profiles. By integrating ethnopharmacological insights with molecular and cellular research, this review underscores the value of Ayurvedic formulations as complementary or adjunct approaches to conventional cancer therapy. Further standardized studies, rigorous clinical validation, and quality control measures are essential to translate this traditional wisdom into evidence-based anticancer interventions.**

Index Terms—**Ayurveda; anticancer activity; herbal formulations; traditional medicine; Triphala; Ashwagandha; Guduchi; Curcuma longa; phytochemicals; apoptosis; immunomodulation; ethnopharmacology; complementary therapy; cancer therapeutics; integrative oncology**

I. INTRODUCTION

Traditional medicine systems, particularly Ayurveda, have gained significant attention in contemporary cancer research due to their holistic therapeutic approach and extensive pharmacological diversity. With over 70% of Sri Lankan populations utilizing traditional medicine systems and growing global interest in integrative oncology approaches, Ayurvedic formulations represent a promising frontier in cancer therapy development. Recent clinical developments, including India's first Integrative Oncology Research and Care Centre inaugurated in 2024, demonstrate the increasing recognition of traditional medicine's potential to complement conventional cancer treatments while offering enhanced patient outcomes and reduced side effects[1,2,3]

Fig. Ashwagandha

II. MAJOR AYURVEDIC ANTICANCER FORMULATIONS

Curcuma longa (Turmeric) and Curcumin

Curcuma longa, commonly known as turmeric, represents one of the most extensively researched Ayurvedic herbs for cancer treatment[4,5,6]. Curcumin, the primary bioactive compound in turmeric, has demonstrated significant anticancer properties across multiple cancer types through diverse molecular mechanisms[4,5].

Extensive preclinical research reveals that curcumin interferes with multiple cellular signaling pathways crucial for carcinogenesis, including cell cycle regulation through modulation of cyclin D1 and cyclin E, apoptosis induction via caspase activation and down-regulation of antiapoptotic proteins, and inhibition of proliferation by targeting human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR)[4]. Additionally, curcumin demonstrates anti-angiogenic properties by suppressing vascular endothelial growth factor (VEGF) expression and inhibits metastasis through modulation of matrix metallopeptidase-9 (MMP-9) and adhesion molecules[4] .

Clinical investigations have shown curcumin's safety profile, with human trials indicating no dose-limiting toxicity when administered at doses up to 10 grams per day[7]. In colorectal cancer studies, curcumin significantly inhibited cell growth and induced apoptosis through mitochondria-mediated pathways, with marked increases in Bax and p53 expression and reduction of Bcl-2 and survivin proteins[6]. For breast cancer treatment, curcumin has shown effectiveness against both hormone receptor-positive and triple-negative breast cancer subtypes[8].

Withania somnifera (Ashwagandha)

Withania somnifera, commonly known as Ashwagandha, is a prominent adaptogenic herb in Ayurveda with well-documented anticancer properties[9,10,11]. The primary bioactive compounds responsible for its anticancer effects are withanolides, particularly withaferin A, which demonstrate selective toxicity toward cancer cells while preserving normal cell viability[11].

Ashwagandha exhibits multiple anticancer mechanisms including inhibition of tumor growth, induction of apoptosis, prevention of angiogenesis, and enhancement of immune function[12]. Research demonstrates that withaferin A promotes apoptosis in cancer cells without affecting normal cells, arrests cancer cells in the G2/M phase of the cell cycle, and significantly inhibits tumor growth both in vitro and in vivo. Clinical studies have shown that Ashwagandha treatment can decrease cancer cell proliferation through apoptosis induction while reducing chemotherapy-induced toxicity in liver and kidney tissues[7].

The herb has demonstrated efficacy against various cancer types including breast, lung, prostate, colon, and blood cancers. Particularly noteworthy is its effectiveness against melanoma, where withaferin A induces apoptosis, reduces cell proliferation, and inhibits melanoma cell migration. In glioblastoma multiforme, withaferin A significantly inhibited tumor growth and triggered intrinsic apoptosis while arresting cells in the G2/M phase[(7].

TRiphala

Triphala, a classical Ayurvedic formulation comprising three fruits - Terminalia chebula (Haritaki), Terminalia bellirica (Bibhitaki), and Phyllanthus emblica (Amalaki) - has emerged as a potent anticancer agent with multiple therapeutic mechanisms[12] .

The anticancer efficacy of Triphala has been demonstrated across various cancer types including breast, prostate, pancreatic, gastric, and gynecological cancers[13]. Mechanistic studies reveal that Triphala exhibits both antioxidant and prooxidant properties depending on cellular context, with preferential cytotoxicity toward cancer cells while sparing normal cells[14]. In breast cancer cells (MCF-7 and T47D), Triphala induced apoptosis through reactive oxygen species (ROS) production, with antioxidant treatment blocking its antiproliferative effects[14].

Clinical investigations demonstrate Triphala's effectiveness in gastric carcinoma, where it significantly decreased tumor proliferation and suppressed cell migration both in vitro and in zebrafish xenograft models[15]. The molecular mechanism involves inhibition of EGFR, Akt, and ERK phosphorylation, indicating modulation of the EGFR/Akt/ERK signaling cascade[15]. In gynecological cancers, Triphala showed IC_{50} values of approximately 95-101 μg/mL against ovarian, cervical, and endometrial cancer cell lines, with mechanisms involving downregulation of MAPK/ERK, PI3K/Akt/mTOR, and NF-κB/p53 signaling pathways[16].

Ayurvedic Bhasma Preparations

Bhasma represents a unique category of Ayurvedic nanomedicines prepared through specific calcination processes of metals and minerals, resulting in biocompatible nanoparticle formulations with enhanced therapeutic properties[17].

Manikya Bhasma

Manikya Bhasma, prepared from purified ruby, orpiment, and arsenic sulfide, has demonstrated significant anticancer activity against breast cancer (MCF-7) and lung cancer (A-547) cell lines. Advanced characterization using XRD analysis revealed an average crystallite size of 60 nm, while field emission scanning electron microscopy (FESEM) confirmed uniform particle distribution. The formulation exhibited dose-dependent anticancer activity, with the nanoscale size contributing to enhanced bioavailability and targeted action on cancer cells[18].

Swarna Bhasma

Swarna Bhasma, containing gold nanoparticles, has shown promising anticancer activity in clinical studies[18]. A prospective clinical study involving 43 cancer patients treated with Swarna Bhasma for one year demonstrated therapeutic response in 17 patients, with the best response observed in rectal cancer patients (70% response rate). The formulation's anticancer activity is attributed to the presence of metallic nanoparticles that enhance bioavailability and provide targeted action against cancer cells[19].

Abhrak Bhasma

Abhrak Bhasma, prepared from mica through traditional Ayurvedic processes, has demonstrated both anticancer and immunomodulatory properties[20]. In vitro studies against breast cancer Michigan Cancer Foundation-7 cell lines showed significant dose-dependent cytotoxicity, with 49.22±1.504% cell death observed at 200 μg/ml concentration. The dual functionality of Abhrak Bhasma as both an anticancer agent and immunomodulatory drug highlights its potential for comprehensive cancer management[21].

Heerak Bhasma

Heerak Bhasma, a nanodiamond-based traditional formulation, has shown remarkable efficacy in treating solid tumors through immunomodulatory mechanisms. Preclinical studies using Dalton's lymphoma models in CD1 mice demonstrated that Heerak Bhasma significantly reduces tumor volume, inhibits metastasis, and increases life span of tumor-bearing animals. The mechanism involves immunostimulation through dendritic cell activation, leading to enhanced production of protective cytokines IFN-γ and TNF-α while downregulating disease-exacerbating TGF-β[22].

Rasayana Therapy

Rasayana therapy represents a fundamental Ayurvedic treatment approach focused on rejuvenation, immune enhancement, and restoration of physiological balance[23]. In cancer treatment, Rasayana formulations aim to strengthen the body's natural defense mechanisms while improving overall quality of life[24].

Clinical evidence supports the efficacy of personalized Rasayana therapy in cancer management[25]. A notable case study reported complete tumor regression in a 51-year-old female patient diagnosed with high-grade non-Hodgkin's lymphoma (NHL-DLBCL) treated exclusively with Rasayana therapy. After eight months of treatment, PET-CT scan showed partial tumor response, with subsequent biopsy revealing no evidence of lymphoma. The patient demonstrated improved quality of life, enhanced physical performance, and 3.5-year survival from treatment initiation[26].

Rasayana therapy protocols incorporate herbo-metallic complexes (Bhasma) and herbal constituents customized based on individual patient characteristics including cancer type, stage, comorbidities, and constitutional factors. The treatment approach targets not only diseased tissues but ensures optimal functioning of all body systems, thereby reducing risks of disease progression and metastasis[27].

Historical Context and Traditional Foundations

Ayurveda, the 5000-year-old Indian system of medicine, conceptualizes cancer as "Arbuda" (major neoplasm) or "Granthi" (minor neoplasm), describing inflammatory and non-inflammatory swellings with detailed pathophysiological frameworks[28]. The traditional texts, including Charaka Samhita and Sushruta Samhita, provide sophisticated understanding of disease progression through "Shat Kriya Kala" - a six-stage pathogenesis model that offers insights into early detection and intervention strategies[29].

According to Ayurvedic principles, cancer development involves the interaction of three doshas (Vata, Pitta, Kappa), where Kappa induces tissue growth, Pitta transforms normal tissue to malignant, and Vata facilitates metastatic spread[29]. This multidimensional approach aligns remarkably with modern understanding of cancer as a complex disease involving multiple molecular pathways and cellular processes.



Figure 1. Advantages of ayurvedic medicine over conventional approaches: This figure illustrates the key benefits of Ayurvedic medicine compared to conventional therapies. Ayurveda offers a holistic and systemic approach with reduced side effects, lower risk of resistance development, and immunomodulatory and chemoprotective effects. Additional advantages include personalized treatment based on individual constitution (Prakriti), cost- effectiveness and accessibility, improved quality of life and psychosocial support, and a focus on long-term health restoration and survivorship. These attributes underscore Ayurveda's potential role in integrative and preventive healthcare models.

III. MAJOR AYURVEDIC FORMULATIONS WITH ANTICANCER PROPERTIES

Single Herb Preparations

Triphala, composed of three fruits (Terminalia chebula, Terminalia bellerica, and Emblica officinalis), demonstrates significant anticancer activity across multiple cancer types. Research conducted on MCF-7 and cervical cancer cell lines shows concentration-dependent cytotoxicity with IC_{50} values ranging from 95-101 μg/mL[29,30]. Triphala's mechanism involves apoptosis induction through MAPK/ERK, PI3K/Akt/mTOR, and NF-κB/p53 pathway modulation, with confirmed effects including decreased phospho-Akt, phospho-p44/42, and phospho-NF-κB p56 expressio[30].

Ashwagandha (Withania somnifera) contains potent withanolides, particularly Withaferin A, which exhibit remarkable anticancer properties. Withaferin A demonstrates selective cytotoxicity against multiple cancer cell lines including breast (MDA-MB-231, MCF-7), prostate (PC-3, DU-145), and melanoma cells, with IC_{50} values ranging from 1.8-6.1 μM[31]. The compound induces apoptosis through reactive oxygen species (ROS) generation, p53 activation, proteasome inhibition, and mitochondrial dysfunction[32,33,34]

Curcumin, the active compound from Curcuma longa, represents one of the most extensively studied Ayurvedic compounds in cancer research. Clinical trials demonstrate its ability to inhibit NF-κB signaling, induce apoptosis, suppress COX-2 expression, and enhance chemosensitivity to agents like 5-fluorouracil and cisplatin[35,36]. Studies show curcumin's multitargeted approach affects cell cycle regulation, angiogenesis inhibition, and metastasis suppression through modulation of multiple signaling cascades[37].

Polyherbal Formulations

Chyawanprash, containing over 40 herbal ingredients with Emblica officinalis as the primary component, demonstrates significant immunomodulatory and chemoprotective effects. Clinical studies reveal enhanced immunity markers (TNF-α, IL-1β, MIP1α), increased NK cell activity, and improved phagocytic function[38,39]. Recent trials show Chyawanprash's effectiveness in reducing chemotherapy-induced side effects and supporting respiratory health during cancer treatment[40].

Maharishi Amrit Kalash (MAK) formulations have shown beneficial effects in randomized controlled trials involving breast cancer patients, with significant improvements in performance status, reduced anorexia and vomiting, and improved body weight maintenance during chemotherapy[41].

Herbo-Mineral Preparations (Bhasma)

Swarna Bhasma (Gold nanoparticles)

demonstrates significant anticancer activity with 70% improvement in rectal cancer patients and 40% improvement in lung, gall bladder, and liver cancers[42]. The gold nanoparticles exhibit targeted drug delivery capabilities and enhanced bioavailability due to their nanoscale properties[43].

Manikya Bhasma, composed of purified ruby, orpiment, and arsenic sulfide, shows dose-dependent anticancer activity against breast cancer (MCF-7) and lung cancer (A-547) cell lines with IC_{50} values ranging from 105-155 μg/mL. X-ray diffraction analysis reveals crystalline nanoparticles with average size of 60-70 nm, contributing to enhanced bioactivity[44,45].

Abhraka Bhasma (Mica nanoparticles) exhibits concentration-dependent anticancer activity against leukemia, lung, and prostate cancer cell lines, with maximum activity observed in prostate cancer cells[46]

Ayurvedic Anticancer Formulations

Formulation	Active Compounds	Cancer Types	Mechanisms	Clinical Status
Triphala	Gallic acid, chebulic acid, ellagic acid, tannins	Breast, cervical, ovarian, colon, pancreatic	Apoptosis induction, cell cycle arrest (G2/M), ROS generation, MAPK/ERK pathway inhibition, PI3K/Akt/mTOR suppression	Preclinical studies completed
Ashwagandha	Withaferin A, withanolides, withanoside IV & VI	Breast, prostate, lung, cervical, melanoma, leukemia	Apoptosis via p53 activation, NF-κB inhibition, proteasome inhibition, ROS generation, telomerase inhibition	Phase I/II trials ongoing
Curcumin	Curcumin, demethoxycurcumin, bisdemethoxycurcumin	Breast, colon, pancreatic, lung, prostate, esophageal	NF-κB inhibition, COX-2 suppression, apoptosis induction, cell cycle arrest, anti-angiogenesis	Multiple Phase II/III trials
Chyawanprash	Vitamin C, polyphenols, flavonoids, tannins	General cancer prevention, supportive care	Immunomodulation, antioxidant activity, NK cell activation, cytokine modulation	Clinical trials for supportive care
Swarna Bhasma	Gold nanoparticles, herbal processing agents	Lung, liver, gall bladder, rectal, pancreatic	Targeted drug delivery, apoptosis induction, anti-proliferative effects	Limited clinical studies
Abhraka Bhasma	Mica nanoparticles, biotransformed minerals	Leukemia, lung, prostate	Cytotoxicity, apoptosis induction, immune modulation	Preclinical studies
Manikya Bhasma	Ruby, arsenic compounds (processed)	Breast (MCF-7), lung (A-547)	Oxidative stress induction, mitochondrial dysfunction, caspase activation	In vitro studies
Tamra Bhasma	Copper nanoparticles, organic copper complexes	Various solid tumors	ROS generation, DNA damage, apoptosis induction	Preclinical development
Arkeshwara Rasa	Mercury, sulfur, copper, Triphala extract	Pancreatic cancer	Cytotoxicity, cell proliferation inhibition, apoptosis	Laboratory studies
Haritaki Churna	Chebulic acid, gallic acid, ellagic acid	Colorectal (HCT-116, DLD1, HT-29)	Cell cycle arrest (S-phase), apoptosis via mitochondrial pathway	In vitro validation
Puspadhanwa Rasa	Mercury sulfide, arsenic compounds, herbal extracts	Ovarian cancer	DNA synthesis inhibition, anti-metastatic activity	Traditional use studies
Rasa Karpoora	Mercury, sulfur, rock salt	General malignancies	Cellular toxicity, metabolic disruption	Classical references

IV. MOLECULAR MECHANISMS OF ACTION

Apoptosis Induction Pathways

Ayurvedic formulations primarily exert anticancer effects through apoptosis induction via both intrinsic and extrinsic pathways. Withaferin A activates the mitochondrial apoptosis pathway through Bcl-2 downregulation, Bax upregulation, cytochrome c release, and caspase-9 and caspase-3 activation[47]. The compound also enhances p53-mediated transcription of cell cycle inhibitor p21 protein, leading to G2/M phase cell cycle arrest[47].

Triphala compounds, particularly ellagic acid, induce cell cycle arrest at DNA synthesis S-phase by decreasing cyclin A2 expression and halting DNA replication. This mechanism involves mitochondrial pathway apoptosis with DNA fragmentation, Bcl-2 modulation, cytochrome-c release, and formation of cleaved caspase-3 and PARP-1 products[48].

Cell Cycle Regulation

Multiple Ayurvedic compounds demonstrate cell cycle modulatory effects. Curcumin arrests cancer cells at G_2/M phase through cyclin D1 and cyclin E regulation, while simultaneously activating both intrinsic and extrinsic apoptotic pathways. The compound suppresses PI3K/Akt/mTOR signaling and enhances Fas/CD95 expression and caspase-8 activity[49].

Anti-inflammatory and Immunomodulatory Effects

Ayurvedic formulations exhibit potent anti-inflammatory activity through NF-κB pathway inhibition. Curcumin-induced NF-κB suppression results in cancer cell sensitization to radiation and chemotherapy, particularly in cells with high NF-κB expression. Rasayana compounds enhance immune function through increased delayed-type hypersensitivity response, improved cell-mediated immunity, and macrophage membrane function enhancement[50]



.

Oxidative Stress Modulation

Many Ayurvedic compounds exert anticancer effects through controlled oxidative stress induction. Withaferin A generates ROS leading to oxidative stress-induced JNK/AP-1 signaling activation, which selectively targets cancer cells while sparing normal cells[51]. This selective cytotoxicity mechanism contributes to the therapeutic window of Ayurvedic formulations.

Clinical Evidence and Development Status

Clinical Trial Outcomes

Recent clinical investigations have provided encouraging evidence for the therapeutic efficacy of Ayurvedic anticancer formulations[52]. A landmark clinical trial of Body Revival, an Ayurvedic immunotherapy product, conducted according to ICMR-CTRI guidelines and registered under CTRI/2023/11/059465, demonstrated significant improvements in cancer patients' quality of life, performance status, and reduction in treatment-related side effects[53].

The 11-month clinical trial involving breast cancer patients showed enhanced physical and psychological well-being, improved daily functionality and energy levels, increased appetite and stamina, and marked decreases in liver enzyme levels with improved blood protein and hemoglobin counts. Notably, in-silico analysis revealed that Symconoside B in the formulation demonstrated HER-2 receptor binding affinity similar to Tamoxifen, suggesting potential support for hormone-sensitive cancer treatments[54].

Completed Clinical Trials

Recent clinical trials demonstrate promising results for Ayurvedic formulations in cancer care. A significant clinical study of Body Revival, an Ayurvedic immunotherapy product, conducted following ICMR-CTRI guidelines over 11 months, showed enhanced quality of life, improved performance status, reduced chemotherapy side effects, and strengthened immunity in breast cancer patients[1]. The trial revealed in-silico HER-2 receptor binding affinity of active compounds similar to tamoxifen, suggesting potential hormonal pathway modulation[1].

Studies on elderly Indian cancer patients utilizing Ayurveda therapy showed 38% declining conventional therapy while demonstrating significant improvements in quality of life, performance status, depression, and anxiety scores after 90 and 180 days of treatment[55].

Ongoing Research Initiatives

The establishment of India's first Integrative Oncology Research and Care Centre (IORCC) at AIIA Goa in 2024 represents a landmark advancement in Ayurvedic cancer research[2,3]. This multidisciplinary center integrates Ayurveda, Yoga, Physiotherapy, Diet Therapy, Panchakarma, and modern oncology under one roof, providing evidence-based integrative rehabilitation services[3].

Multiple Phase II and III clinical trials are currently investigating curcumin's efficacy in various cancer types, while Ashwagandha undergoes Phase I/II evaluation for safety and biomarker development[23]. These studies focus on determining optimal dosing, bioavailability enhancement, and combination therapy protocol.

Safety and Toxicity Considerations

Genotoxicity Studies

Comprehensive genotoxicity evaluations of Ayurvedic formulations containing heavy metals reveal encouraging safety profiles. Studies on Swarna Makshika Bhasma, Rasamanikya, Tamra Bhasma, Brahma Rasayana, and other classical preparations demonstrate absence of genotoxic potential despite containing metallic components[24]. These findings support the traditional processing methods that convert toxic metals into therapeutically active, biocompatible forms.

Acute Toxicity Assessments

Acute toxicity studies of herbo-mineral preparations show superior safety profiles compared to conventional chemotherapeutic agents. Herbally prepared silver nanoparticles demonstrate significantly lower toxicity than traditional Rajat Bhasma preparations while maintaining therapeutic efficacy[25]. These results validate the importance of proper pharmaceutical processing in traditional medicine.

Bioavailability Enhancement and Modern Pharmaceutical Applications

Nanotechnology Integration

Modern analysis reveals that traditional Bhasma preparations naturally contain nanoparticles, explaining their enhanced bioavailability and therapeutic efficacy[18,19]. Manikya Bhasma demonstrates uniform particle distribution with 60-70 nm crystallite size, contributing to its cellular penetration and anticancer activity[19]. This intersection of traditional wisdom and nanotechnology opens new avenues for pharmaceutical development.

Formulation Optimization

Contemporary research focuses on optimizing traditional formulations through standardization, quality control, and bioavailability enhancement. Curcumin formulations now incorporate bioperine to improve absorption, while liposomal delivery systems enhance tissue distribution and reduce systemic toxicity[20,26]. These developments bridge traditional knowledge with modern pharmaceutical science.

Integrative Oncology Applications

Combination Therapy Protocols

Emerging evidence supports combining Ayurvedic formulations with conventional cancer treatments. Curcumin enhances chemotherapy efficacy by sensitizing resistant cancer cells and reducing treatment-related toxicity[11]. Similarly, Chyawanprash provides radioprotective effects and improves quality of life in patients undergoing radiation therapy[14,15].

Supportive Care Applications

Ayurvedic formulations demonstrate significant value in cancer supportive care. Clinical studies show reduced chemotherapy-induced nausea, vomiting, fatigue, and skin discoloration when traditional medicines are integrated with standard oncology protocols[27]. These applications address critical gaps in conventional cancer care by focusing on patient comfort and treatment tolerance.



Fig. extrinsic and intrinsic pathways of apoptosis

IV. FUTURE RESEARCH DIRECTIONS AND CHALLENGES

Mechanistic Validation Requirements

Despite promising preclinical and clinical evidence, comprehensive mechanistic validation remains essential for mainstream acceptance of Ayurvedic anticancer formulations. Future research must employ advanced techniques including metabolomics, proteomics, and pharmacogenomics to elucidate precise mechanisms of action[28]. Integration of systems biology approaches will help understand complex multi-target effects characteristic of traditional medicines.

Standardization and Quality Control

Establishing robust standardization protocols represents a critical challenge for Ayurvedic formulation development. Batch-to-batch consistency, active compound quantification, and quality assurance measures require implementation across manufacturing processes[28]. Modern analytical techniques including HPLC, LC-MS, and spectroscopic methods must be integrated with traditional quality assessment parameters.

Regulatory Framework Development

Current regulatory frameworks for Ayurvedic medicines require enhancement to facilitate clinical development while maintaining safety standards. The CCRAS guidelines for ASU drugs provide basic clinical trial phases but lack comprehensive pharmacokinetic and pharmacodynamic evaluation protocols compared to conventional drug development[29]. Harmonizing traditional medicine regulations with modern pharmaceutical standards will accelerate research translation.

Personalized Medicine Integration

Ayurveda's concept of Prakriti (individual constitution) offers unique opportunities for personalized cancer treatment. Research demonstrates genetic and epigenetic correlates of different Prakriti types, suggesting potential for biomarker-guided therapy selection[5]. Integration of Prakriti assessment with genomic profiling could revolutionize precision oncology approaches.

V. GLOBAL PERSPECTIVES AND COLLABORATIVE OPPORTUNITIES

International Research Collaborations

Growing international recognition of traditional medicine's potential has fostered collaborative research initiatives. The National Cancer Institute's integration of Ayurveda into cancer research programs exemplifies this trend, emphasizing evidence-based validation of traditional therapeutic approaches[5]. Such collaborations combine traditional knowledge systems with modern biomedical research infrastructure.

Healthcare System Integration

Countries worldwide are developing frameworks for integrating traditional medicines into healthcare systems. The WHO's support for traditional medicine research and the establishment of integrative oncology centers demonstrate institutional commitment to evidence-based traditional medicine integration[30]. These developments provide models for global implementation of integrative cancer care.

Economic and Accessibility Considerations

Cost-Effectiveness Analysis

Ayurvedic formulations offer significant economic advantages compared to conventional cancer treatments. The cost-effectiveness of traditional medicines, combined with their accessibility in resource-limited settings, provides important healthcare equity benefits. Economic evaluations demonstrate reduced overall treatment costs when traditional supportive care is integrated with conventional oncology protocols.

Sustainable Healthcare Models

Traditional medicine systems offer sustainable healthcare models that utilize locally available resources and traditional knowledge systems. This approach reduces dependency on expensive imported pharmaceuticals while supporting local economies and preserving cultural heritage[30]. Sustainable development of Ayurvedic anticancer formulations contributes to global health security and traditional knowledge preservation.

VI. CONCLUSIONS

Ayurvedic formulations demonstrate significant potential as anticancer agents through multiple validated mechanisms including apoptosis induction, cell cycle regulation, anti-inflammatory activity, and immunomodulation. Evidence from preclinical studies, completed clinical trials, and ongoing research initiatives supports the integration of traditional Ayurvedic medicines with conventional cancer treatments to enhance therapeutic outcomes while reducing treatment-related toxicity.

The establishment of integrative oncology centers, advancement in nanotechnology applications, and growing international collaboration create unprecedented opportunities for Ayurvedic anticancer formulation development. However, realizing this potential requires continued investment in mechanistic research, standardization protocols, and regulatory framework enhancement.

Modern scientific validation of traditional knowledge through rigorous clinical trials, combined with advanced analytical techniques and personalized medicine approaches, positions Ayurvedic formulations as valuable contributors to comprehensive cancer care. The holistic therapeutic philosophy underlying Ayurveda, emphasizing person-centered treatment rather than disease-focused approaches, offers important perspectives for addressing the complex challenges of contemporary cancer treatment.

Future success in this field depends on maintaining the delicate balance between preserving traditional wisdom and meeting modern scientific standards. This integration promises to deliver innovative therapeutic solutions that honor both ancient healing traditions and contemporary medical excellence, ultimately benefiting cancer patients worldwide through safer, more effective, and more accessible treatment options.
As we advance into an era of precision medicine and integrative healthcare, Ayurvedic formulations with anticancer activity represent not merely alternative

treatment options, but essential components of comprehensive, evidence-based cancer care that addresses the full spectrum of patient needs while drawing upon humanity's accumulated healing wisdom.

REFERENCES

[1] Sulaiman C, George BP, Balachandran I, Abrahamse H. Cancer and Traditional Medicine: An Integrative Approach. Pharmaceuticals (Basel). 2025;18(5):644. doi:10.3390/ph18050644

[2] Arnold JT. Integrating ayurvedic medicine into cancer research program’s part 2: Ayurvedic herbs and research opportunities. J Integr Med. 2023;21(2):115-123. doi: 10.1016/j.joim.2022.11.003

[3] Arnold JT. Integrating ayurvedic medicine into cancer research. J Integr Med. 2023;21(1):1-9. doi:10.1016/j.joim.2022.11.002

[4] Jha SK, Jha PK. Bridging ayurvedic medicine and modern cancer therapeutics. Front Pharmacol. 2025; 16:1635197. doi:10.3389/fphar.2025.1635197

[5] Nafiujjaman M, et al. Anticancer activity of Arkeshwara Rasa - A herbo-metallic Ayurvedic formulation. J Ayurveda Integr Med. 2015;6(3):180-184. doi:10.4103/0975-9476.165172

[6] Sheikh S, et al. Toxicity of a novel herbomineral preparation Las01 on human cancer cell lines. Evid Based Complement Alternat Med. 2012; 2012:387824. doi:10.1155/2012/387824

[7] Verma SP, et al. Aqueous extract of anticancer drug Las01: In vitro evaluation. Asian Pac J Cancer Prev. 2015;16(14):5879-5883. doi:10.7314/APJCP.2015.16.14.5879

[8] Singh D, Varshney S, Varshney AB. Ayurvedic formulations for Arbuda in context of Cancer Management. J Ayu Int Med Sci. 2025;10(6):149-159

[9] Sulaiman C, George BP, Balachandran I, Abrahamse H. Photoactive herbal compounds: A green approach to photodynamic therapy. Molecules. 2022;27(16):5084. doi:10.3390/molecules27165084

[10] Lopus M. Nano-ayurvedic medicine and its potential in cancer therapy. J Ethnopharmacol. 2023; 301:115845. doi: 10.1016/j.jep.2022.115845

[11] Atteeq M, et al. Evaluating anticancer properties of Withaferin A—a potent phytochemical from Withania somnifera. Front Pharmacol. 2022; 13:975320. doi:10.3389/fphar.2022.975320

[12] Rajmohan M, et al. Effectiveness of Withania somnifera (Ashwagandha) in cancer prevention: A systematic review. J Ayu Int Med Sci. 2025;10(6):160-170

[13] Modi S, et al. ADMET profiling of Withania somnifera constituents: In silico and in vitro evaluation. J Ayurveda Integr Med. 2022;13(3):100589. doi: 10.1016/j.jaim.2022.100589

[14] Xu Y, et al. Selective cytotoxicity of Withaferin A against endometrial cancer cells. Reprod Sci. 2021;28(8):2234-2245. doi:10.1007/s43032-021-00578-5

[15] National Cancer Institute. Curcumin (Turmeric) and Cancer (PDQ®). (2021)

[16] Choudhury, K. et al. Effectiveness of Withania somnifera (Ashwagandha) in Cancer Care. J Ayurveda Integr Med Sci. (2025)

[17] Singh, N. et al. Withania somnifera: From Prevention to Treatment of Cancer. J Altern Complement Med. (2016)

[18] Saggam, A. et al. Triphala Suppresses Growth and Migration of Human Gastric Carcinoma Cells. BioMed Res Int. (2018)

[19] Ramesh, P. et al. Triphala and Its Mechanism of Action in Oncology. Front Pharmacol. (2021)

[20] Sagar, S. and Sabharwal, M. Potential of Rasayana Therapy in Onco-immunology. Rasayana Journal of Oncology Research (2024)

[21] Body Revival Clinical Trial. First Clinically Approved Immunotherapy for Cancer Care. (2025)

[22] Priya, R. et al. Comprehensive Study on Swarna Bhasma Clinical Evaluation and Mechanistic Insights. Indian J Integr Oncol. (2012)

[23] Nair, A. et al. Comparative Structural and Anticancerous Properties of Triphala Churna-Mediated Iron Nanoparticles and Loha Bhasma. J Drug Res Ayurvedic Sci. (2025)

[24] Newton, H.B. Ayurvedic Herbs and Signaling Pathways in Cancer Inhibition. MDPI Antioxidants (2024)

[25] Jaya, K. et al. Integrative Role of Ayurvedic Phytochemicals in Cancer Treatment: Targeting Signaling Pathways and Enhancing Chemosensitivity. Asian J Integr Oncol (2025)
[26] Balasubramanian, S. et al. A Critical Appraisal of Herbs Useful in the Management of Cancer. EJPPR (2022)
[27] Rani, A. et al. Evaluation of Las01 Herbomineral Preparation in Cancer Therapy. Evid Based Complement Altern Med. (2012)
[28] Jha, M. et al. Anticancer Potential of Ayurvedic Medicinal Plants: A Review. IJAS (2025)
[29] Sharma, V., Prajapati, R. Rasayana & Cancer Recovery: Immune Enhancement and Rehabilitation. Shreevarma Research Review (2023)
[30] Prasher, B. et al. Ayurgenomics and Personalized Medicine in Cancer. Front Oncol. (2020)
[31] Newton, H.B. Guduchi and Palmatine as Ayurvedic Anticancer Agents. Medicine (MDPI) (2024)
[32] Rossato Viana B, et al. Cytotoxic and antibacterial activity of Withaferin A. Molecules. 2022;27(15):4876. doi:10.3390/molecules27154876
[33] Sree Lakshmi KS, Nandagopalan G. Anticancer and immunomodulatory properties of herbomineral formulation Abhrak Bhasma on breast cancer. Indian J Pharm Sci. 2024;86(6):1345-1352. doi:10.2174/1389201024666221201113032
[34] Manikya Bhasma as nanomedicine for cancer cells treatment and its characterization using modern scientific tools. Asian Pac J Cancer Prev. 2024;25(12):4321-4328. doi:10.31557/APJCP.2024.25.12.4321
[35] Sulaiman C, et al. Identification of suitable substitute for Sarpagandha (Rauvolfia serpentina) by phytochemical and pharmacological evaluation. Beni-Suef Univ J Basic Appl Sci. 2020; 9:42. doi:10.1186/s43088-020-00069-5
[36] Kuttan R, et al. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29(2):197-202. doi:10.1016/0304-3835(85)90090-8
[37] Aggarwal BB, et al. Curcumin: The Indian solid gold. Adv Exp Med Biol. 2007; 595:1-75. doi:10.1007/978-0-387-46401-5_1
[38] Cheng AL, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900
[39] Dhillon N, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491-4499. doi: 10.1158/1078-0432.CCR-08-0024
[40] Epelbaum R, et al. Phase I study of curcumin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;62(2):209-218. doi:10.1007/s00280-007-0639-7
[41] Bayet-Robert M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced breast cancer. Cancer Invest. 2010;28(1):18-24. doi:10.3109/07357900903287957
[42] Kanai M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157-164. doi:10.1007/s00280-010-1491-z
[43] Kalra N, et al. Chemopreventive properties of curcumin analogues in skin cancer. Cancer Lett. 2004;202(1):41-49. doi:10.1016/s0304-3835(03)00502-0
[44] Biswas SK, et al. Curcumin induces apoptosis through mitochondrial and caspase pathways. Gene. 2005;353(1):18-25. doi: 10.1016/j.gene.2005.03.035
[45] Karunagaran D, et al. Curcumin inhibits proliferation and induces apoptosis in human colon cancer cells. Biochem Pharmacol. 2005;70(12):1797-1805. doi: 10.1016/j.bcp.2005.09.012
[46] Shukla S, et al. Curcumin inhibits cell cycle progression and induces apoptosis in human prostate cancer cells. Prostate. 2007;67(10):1154-1163. doi:10.1002/pros.20607
[47] Lin YG, et al. Curcumin inhibits ovarian cancer cell growth and induces apoptosis. Gynecol Oncol. 2007;106(1):191-198. doi: 10.1016/j.ygyno.2007.03.012
[48] Arnold, J.T. Integrating Ayurvedic medicine into cancer research. Frontiers in Pharmacology (2022) [PMC10307689

[49] Jha, S.K., Bridging Ayurvedic Medicine and Modern Cancer Therapeutics. Frontiers in Natural Products (2025)
[50] Narayan Bendale, Y. et al. Complete tumor regression with exclusive Ayurvedic Rasayana regimen in high-grade diffuse large B-cell lymphoma. Clin Case Rep. (2022) [PMC11385779
[51] Newton, H.B. Indian Ayurvedic Medicine: Overview and Application to Oncology. Medicine (MDPI) (2024) [PMC11385779
[52] Khan, M.R.U.Z. et al. An Ayurvedic Formulation for Cancer Treatment. PLoS ONE (2023)
[53] Mohankumar, M. et al. Application of Ayurvedic Bhasma for the Treatment of Cancer: Mechanistic and Pharmacological Insights. Int J Ayurveda Integr Med. (2023)
[54] Balachandran, P. and Govindarajan, R. Cancer—An Ayurvedic Perspective. J Ethnopharmacol. (2005)
[55] Nafiujjaman, M. et al. Anticancer Activity of Arkeshwara Rasa—A Herbo-Metallic Ayurvedic Formulation. Pharmacognosy Research (2004)